missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Mouse Ephrin-A1 Antibody, R&D Systems™

Rat Monoclonal Antibody
Brand: R&D Systems MAB2116
This item is not returnable.
View return policy
Description
Ephrin-A1 Monoclonal specifically detects Ephrin-A1 in Mouse samples. It is validated for Western Blot.
Specifications
| Ephrin-A1 | |
| Monoclonal | |
| LYOPH | |
| Western Blot 1 ug/mL | |
| P52793 | |
| EFNA1 | |
| Mouse myeloma cell line NS0-derived recombinant mouse Ephrin-A1 Ala18-Ser182 (predicted) Accession # P52793 | |
| 500 μg | |
| Primary | |
| Detects mouse Ephrin-A1 in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse (rm) Ephrin-A2 is observed, and no cross-reactivity with recombinant human Ephrin-A3, -B3, rmEphrin-A4, -A5, -B1, or -B2 is observed. | |
| Mouse | |
| Purified |
| Western Blot | |
| 93036 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| B61, ECKLG, EFL1, EFL-1, EFNA1, EPH-related receptor tyrosine kinase ligand 1, ephrin-A1, EphrinA1, EPLG1TNF alpha-induced protein 4, Immediate early response protein B61, LERK1, LERK1LERK-1, ligand of eph-related kinase 1, TNFAIP4B61, Tumor necrosis factor alpha-induced protein 4, tumor necrosis factor, alpha-induced protein 4 | |
| Rat | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 1942 | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG2b |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction